Samuel B. Brusca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samuel B. Brusca has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Christopher F. Barnett
Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA
6 shared publications Michael A. Solomon
Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA; Cardiovascular Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
3 shared publications- Ran Lee
Sections of Critical Care and Heart Failure Transplant Cardiology, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
3 shared publications Rosy Thachil
Division of Cardiology, Elmhurst Hospital Center, Mount Sinai School of Medicine, New York, NY
3 shared publicationsAnn Gage
Department of Cardiovascular Medicine, Centennial Medical Center, Nashville, TN
2 shared publicationsChristopher Barnett
Department of Medicine, Division of Cardiology, University of California SanFrancisco , San Francisco, CA
2 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4) , e70384
A Team‐Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real‐World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use
Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). This single‐center, retrospective study described oral selexipag dosing patterns and persistence, overall and stratified by history of methamphetamine (meth) use, at an expert center in California, USA, using a multidisciplinary, nurse‐directed protocol entailing frequent follow‐up and individualized side effect management. Medical charts of patients with PAH initiating oral selexipag between January 2016 and March 2023 were abstracted. Patient characteristics and dosing patterns were described up to 14 months post‐initiation. The individualized maintenance dose (IMD) was the first dose maintained for ≥ 14 days after reaching the maximum tolerated dose. Persistence was described using Kaplan–Meier analysis. A total of 200 patients initiated oral selexipag (median age 52 years; 69.5% female; 54.5% White; 70.5% on triple therapy; 41% with a history of meth use). Most patients (89.0%) achieved maintenance (median IMD: 900 μg twice daily; median time to maintenance: 2.5 months). Selexipag persistence at 1 year was 76.2%, with most discontinuations occurring within 2 months of initiation. Similar proportions of patients with and without a history of meth use achieved maintenance (85.4% vs. 91.5%; p = 0.3) and persisted on selexipag at 1 year (74.0% vs. 77.5%; p = 0.9). Using a multidisciplinary nurse‐directed protocol, most patients with PAH were titrated to their IMD and persisted on oral selexipag, including those with a history of meth use. These findings highlight the importance of frequent patient contact for dose adjustment and side effect management, particularly earlier in the titration process.
- 13 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4) , e70384
Open AccessA Team‐Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real‐World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use
Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). This single‐center, retrospective study described oral selexipag dosing patterns and persistence, overall and stratified by history of methamphetamine (meth) use, at an expert center in California, USA, using a multidisciplinary, nurse‐directed protocol entailing frequent follow‐up and individualized side effect management. Medical charts of patients with PAH initiating oral selexipag between January 2016 and March 2023 were abstracted. Patient characteristics and dosing patterns were described up to 14 months post‐initiation. The individualized maintenance dose (IMD) was the first dose maintained for ≥ 14 days after reaching the maximum tolerated dose. Persistence was described using Kaplan–Meier analysis. A total of 200 patients initiated oral selexipag (median age 52 years; 69.5% female; 54.5% White; 70.5% on triple therapy; 41% with a history of meth use). Most patients (89.0%) achieved maintenance (median IMD: 900 μg twice daily; median time to maintenance: 2.5 months). Selexipag persistence at 1 year was 76.2%, with most discontinuations occurring within 2 months of initiation. Similar proportions of patients with and without a history of meth use achieved maintenance (85.4% vs. 91.5%; p = 0.3) and persisted on selexipag at 1 year (74.0% vs. 77.5%; p = 0.9). Using a multidisciplinary nurse‐directed protocol, most patients with PAH were titrated to their IMD and persisted on oral selexipag, including those with a history of meth use. These findings highlight the importance of frequent patient contact for dose adjustment and side effect management, particularly earlier in the titration process.
- Open Access
- 4 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Hyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in veno-arterial extracorporeal membrane oxygenation patients
Aims: Multiple veno-arterial extracorporeal membrane oxygenation (VA-ECMO) studies have recently reported that early hyperoxia is associated with increased mortality; yet, the underlying mechanism is unclear. As prior analyses did not account for native cardiac output or fraction of delivered oxygen, it remains unknown whether hyperoxia is directly injurious or primarily a surrogate of poor intrinsic cardiac function and proximal mixing. This study aims to evaluate whether hyperoxia is an independent predictor of mortality in VA-ECMO patients or whether it primarily reflects impaired native cardiac function. Methods and results: We conducted a single-centre retrospective cohort study of 227 VA-ECMO patients to evaluate the relationship between hyperoxia and intensive care unit (ICU) mortality, accounting for native cardiac index using multivariable regression and principal component analysis. Average PaO2 and cardiac index were analysed as continuous variables. Decreased cardiac index was the strongest independent predictor of ICU mortality in a multivariable regression [odds ratio (OR) 0.22; 95% confidence interval (CI): 0.06–0.70; P = 0.018]. After adjusting for native cardiac index and utilization of advanced therapies (i.e. heart transplant or left ventricular assist device), the association between hyperoxia and mortality became insignificant. Average PaO2 and cardiac index were strongly inversely collinear [variance inflation factor (VIF) = 7.2 and 11.5, respectively], with their interaction term yielding a VIF of 20.3. Non-survivors and survivors who received advanced therapies share similar PC1 score distributions (a weighted composite of average PaO2 and cardiac index) and impaired haemodynamic profiles, including reduced ejection fraction, pulse pressures, and oxygen delivery indices. Conclusion: The association between early hyperoxia and mortality in VA-ECMO is primarily driven by underlying cardiac failure rather than direct oxygen toxicity. The availability of advanced therapies further modifies this relationship, underscoring the need to account for both native cardiac output and heart replacement strategies when evaluating optimal PaO2 targets and the independent effect of hyperoxia on VA-ECMO outcomes.
- 4 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Open AccessHyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in veno-arterial extracorporeal membrane oxygenation patients
Aims: Multiple veno-arterial extracorporeal membrane oxygenation (VA-ECMO) studies have recently reported that early hyperoxia is associated with increased mortality; yet, the underlying mechanism is unclear. As prior analyses did not account for native cardiac output or fraction of delivered oxygen, it remains unknown whether hyperoxia is directly injurious or primarily a surrogate of poor intrinsic cardiac function and proximal mixing. This study aims to evaluate whether hyperoxia is an independent predictor of mortality in VA-ECMO patients or whether it primarily reflects impaired native cardiac function. Methods and results: We conducted a single-centre retrospective cohort study of 227 VA-ECMO patients to evaluate the relationship between hyperoxia and intensive care unit (ICU) mortality, accounting for native cardiac index using multivariable regression and principal component analysis. Average PaO2 and cardiac index were analysed as continuous variables. Decreased cardiac index was the strongest independent predictor of ICU mortality in a multivariable regression [odds ratio (OR) 0.22; 95% confidence interval (CI): 0.06–0.70; P = 0.018]. After adjusting for native cardiac index and utilization of advanced therapies (i.e. heart transplant or left ventricular assist device), the association between hyperoxia and mortality became insignificant. Average PaO2 and cardiac index were strongly inversely collinear [variance inflation factor (VIF) = 7.2 and 11.5, respectively], with their interaction term yielding a VIF of 20.3. Non-survivors and survivors who received advanced therapies share similar PC1 score distributions (a weighted composite of average PaO2 and cardiac index) and impaired haemodynamic profiles, including reduced ejection fraction, pulse pressures, and oxygen delivery indices. Conclusion: The association between early hyperoxia and mortality in VA-ECMO is primarily driven by underlying cardiac failure rather than direct oxygen toxicity. The availability of advanced therapies further modifies this relationship, underscoring the need to account for both native cardiac output and heart replacement strategies when evaluating optimal PaO2 targets and the independent effect of hyperoxia on VA-ECMO outcomes.
- 25 June 2026
- Published by Elsevier in American Heart Journal
- Vol. 301, 107521
The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization
- 25 June 2026
- Published by Elsevier in American Heart Journal
- Vol. 301, 107521
The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization
- Open Access
- 25 March 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3) , 102629
Physician Burnout and Work Satisfaction in the Cardiac Intensive Care Unit
- 25 March 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (3) , 102629
Open AccessPhysician Burnout and Work Satisfaction in the Cardiac Intensive Care Unit
- 21 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (5) , 415-423
Impact of right heart failure in patients with cardiogenic shock
Aims: The prognosis of right heart failure (RHF) is purported to be poor, yet there are limited data detailing the implications of concomitant cardiogenic shock (CS) and RHF. We sought to characterize the prevalence and impact of RHF on patients with CS. Methods and results: We queried the Vizient® Clinical Database to identify adults ≥18 years old admitted 1 October 2015 to 30 June 2023, with a diagnosis of CS. Using inverse probability of treatment weighting (IPTW), adjusting for demographics, comorbidities, and markers of acuity, we compared in-hospital mortality between patients with and without a diagnosis of RHF as well as by Society of Cardiovascular Angiography and Interventions (SCAI) shock stages B through E. We identified 348 919 patients with CS, including 11.3% (n = 39 610) with RHF. Patients with RHF were younger (60.5 vs. 65.5; P < 0.001), more frequently had heart failure (HF) as their primary admission diagnosis (40.8% vs. 23.2%; P < 0.001), and presented in earlier SCAI shock stages. Patients with non-RHF CS were more likely to have acute myocardial infarction (AMI) as primary admission diagnosis (20.7% vs. 8.2%; P < 0.001) and present with out-of-hospital cardiac arrest (11.5% vs. 5.8%; P < 0.001). After adjustment, RHF was associated with a 2.4% [95% confidence interval (CI): 1.9–2.9%; P < 0.001] increase in absolute mortality and when stratified by SCAI shock stage. Patients with isolated RHF were found to have a higher absolute in-hospital mortality [9.8%; 95% (CI): 8.6–11.0%; P < 0.001]. Conclusion: The presence of RHF is associated with increased in-hospital mortality in patients admitted with CS.
- 21 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (5) , 415-423
Impact of right heart failure in patients with cardiogenic shock
Aims: The prognosis of right heart failure (RHF) is purported to be poor, yet there are limited data detailing the implications of concomitant cardiogenic shock (CS) and RHF. We sought to characterize the prevalence and impact of RHF on patients with CS. Methods and results: We queried the Vizient® Clinical Database to identify adults ≥18 years old admitted 1 October 2015 to 30 June 2023, with a diagnosis of CS. Using inverse probability of treatment weighting (IPTW), adjusting for demographics, comorbidities, and markers of acuity, we compared in-hospital mortality between patients with and without a diagnosis of RHF as well as by Society of Cardiovascular Angiography and Interventions (SCAI) shock stages B through E. We identified 348 919 patients with CS, including 11.3% (n = 39 610) with RHF. Patients with RHF were younger (60.5 vs. 65.5; P < 0.001), more frequently had heart failure (HF) as their primary admission diagnosis (40.8% vs. 23.2%; P < 0.001), and presented in earlier SCAI shock stages. Patients with non-RHF CS were more likely to have acute myocardial infarction (AMI) as primary admission diagnosis (20.7% vs. 8.2%; P < 0.001) and present with out-of-hospital cardiac arrest (11.5% vs. 5.8%; P < 0.001). After adjustment, RHF was associated with a 2.4% [95% confidence interval (CI): 1.9–2.9%; P < 0.001] increase in absolute mortality and when stratified by SCAI shock stage. Patients with isolated RHF were found to have a higher absolute in-hospital mortality [9.8%; 95% (CI): 8.6–11.0%; P < 0.001]. Conclusion: The presence of RHF is associated with increased in-hospital mortality in patients admitted with CS.
- Open Access
- 25 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 5 (1) , 102372
Modern Cardiac ICU Care Delivery and the Role of the Cardiac ICU Cardiologist
- 25 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 5 (1) , 102372
Open AccessModern Cardiac ICU Care Delivery and the Role of the Cardiac ICU Cardiologist
- Open Access
- 20 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102355
Characteristics and Survival Among Patients With Cardiogenic Shock Undergoing Mitral Transcatheter Edge-to-Edge Repair
- 20 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102355
Open AccessCharacteristics and Survival Among Patients With Cardiogenic Shock Undergoing Mitral Transcatheter Edge-to-Edge Repair
- Open Access
- 1 December 2024
- Published by Oxford University Press (OUP) in ATS Scholar
- Vol. 5 (4) , 475-478
Close Enough? Feasibility, Success, and Sustainability of Critical Care Echocardiography Curricula
- 1 December 2024
- Published by Oxford University Press (OUP) in ATS Scholar
- Vol. 5 (4) , 475-478
Open AccessClose Enough? Feasibility, Success, and Sustainability of Critical Care Echocardiography Curricula
- Open Access
- 15 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (12) , 826-827
Echocardiographic assessment of right ventricular adaptation and pulmonary embolism: a perfect couple?
Samuel B Brusca, MD, Jessica N Holtzman, MD; Echocardiographic Assessment of Right Ventricular Adaptation and Pulmonary Embolism: A Perfect Couple?, Europe
- 15 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (12) , 826-827
Open AccessEchocardiographic assessment of right ventricular adaptation and pulmonary embolism: a perfect couple?
Samuel B Brusca, MD, Jessica N Holtzman, MD; Echocardiographic Assessment of Right Ventricular Adaptation and Pulmonary Embolism: A Perfect Couple?, Europe